RNASET2 and ovarian cancer: Furthermore, an extension of the above-mentioned studies to other cellular models of human ovarian cancer confirmed the ability of RNASET2 not only to negatively affect cell proliferation and clonogenic activity but also to confer a cell phenotype strictly dependent on the modulation of the tumor cell–extracellular matrix interaction, which, in turn, resulted in decreased oncogenic Src signaling (Figure 1E) [98].